Opportunity for Research Excellence Meeting (Agenda)

Agenda

Day 1 – Thursday, April 29, 2021
9:30 AM – 6:00 PM EDT

OPENING REMARKS & TRIAL UPDATES
9:30 – 10:00
9:30 – 9:35 Welcome Leslie Ford, MD
Division of Cancer Prevention, NCI
9:35 – 9:45 Director’s Remarks Philip Castle, PhD, MPH
Division of Cancer Prevention, NCI
9:45 – 10:00 Consortia / CP-CTNet Trial Updates Eva Szabo, MD
Division of Cancer Prevention, NCI
KEYNOTE SESSION
10:00 – 11:00

Moderators:

Powel Brown, MD, PhD
MD Anderson Cancer Center

Howard Parnes, MD
Division of Cancer Prevention, NCI

10:00 – 10:20
Q&A 10:20 – 10:30
NCAB-BSA Cancer Prevention Working Group Report Judy Garber, MD, MPH
Dana-Farber Cancer Institute
10:30 – 10:50
Q&A 10:50 – 11:00
The Impact of Healthcare Disparities on Cancer Incidence, Mortality, Prevention and Participation in Clinical Trials Otis Brawley, MD
Johns Hopkins University
CLINICAL TRIAL REPORTS
11:00 – 12:15
Moderator:

 

Powel Brown, MD, PhD
MD Anderson Cancer Center
11:00 – 11:15
Q&A 11:15 – 11:25
Phase II Trial of Erlotinib to Reduce Duodenal Polyp Burden in FAP Jewel Samadder, MD, MS
Mayo Clinic
11:25 – 11:40
Q&A 11:40 – 11:50
Window of Opportunity Trial of Low-dose Exemestane in Women with Early-Stage Breast Cancer Bernardo Bonanni, MD
European Institute of Oncology
11:50 – 12:05
Q&A 12:05 – 12:15
Clinical Development of WOKVAC - A Breast Cancer Prevention Vaccine Nora Disis, MD
University of Washington
12:15 – 12:45 LUNCH
CLINICAL TRIAL REPORTS (cont’d)
12:45 – 2:00
Moderator: Powel Brown, MD, PhD
MD Anderson Cancer Center
12:45 – 1:00
Q&A 1:00 – 1:10
Rationale and Design of the Phase II STOP HCC Trial: Statin Operates to Prevent Hepatocellular Carcinoma Shehnaz K. Hussain, PhD, ScM
University of California, Davis
1:10 – 1:25
Q&A 1:25 – 1:35
Lessons Learned: Randomized Crossover Trial Evaluating Detoxication of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Heavy Smokers Julie Bauman, MD, MPH
University of Arizona Cancer Center
1:35 –1:50
Q&A 1:50 – 2:00
Personalized Dosing of Clinical Preventives: The Case of Omega-3 Fatty Acids Dean Brenner, MD
University of Michigan Comprehensive Cancer Center
CLINICAL TRIALS MANAGEMENT
2:00 – 3:00
Moderator: Maggie House, RN, BSN
Division of Cancer Prevention, NCI
2:00 – 2:15
Q&A 2:15 – 2:20
Clinical Trials Simplification Committee Report Maggie House, RN, BSN
Division of Cancer Prevention, NCI
2:20 – 2:35
Q&A 2:35 – 2:40
DCP Accrual Quality Improvement Program (AQuIP) 2021 Ellen Richmond, MS, GNP-BC
Division of Cancer Prevention, NCI
2:40 – 2:55
Q&A 2:55 – 3:00
Demystifying the DMACC KyungMann Kim, PhD
University of Wisconsin-Madison School of Medicine and Public Health
3:00 – 3:10 BREAK
CONCURRENT SESSIONS
3:10 – 5:10 AQuIP THINK TANK DCP AQuIP Think Tank Staff
3:10 – 6:00 CP-CTNet Steering Committee Meeting
(DMACC emailed meeting link to Members)
Eva Szabo, MD
Division of Cancer Prevention, NCI
6:00 – 6:30 Virtual Happy Hour & Discussion

 

Day 2 – Friday, April 30, 2021
10:00 AM – 2:20 PM EDT

TUMOR IMMUNOLOGY SESSION
10:00 – 11:15
Moderator: Asad Umar, DVM, PhD
Division of Cancer Prevention, NCI
10:00 – 10:20
Q&A 10:20 – 10:25
Immunoprevention Jeffrey Schlom, PhD
Center for Cancer Research, NCI
10:25 – 10:45
Q&A 10:45 – 10:50
Prostvac Active Surveillance Study:
Primary Endpoint
Houssein Abdul Sater, MD
Center for Cancer Research, NCI
10:50 – 11:10
Q&A 11:10 – 11:15
Prostvac Active Surveillance Study:
Peripheral Immune Responses
Renee Donahue, PhD
Center for Cancer Research, NCI
11:15 – 11:25 BREAK
HIGH-RISK GENETIC COHORTS
11:25 – 12:40
Moderator: Brandy Heckman-Stoddard, PhD, MPH
Division of Cancer Prevention, NCI
11:25 – 11:45
Q&A 11:45 – 11:50
Naproxen Chemoprevention Promotes Immune Activation in Lynch Syndrome Eduardo Vilar-Sanchez, MD, PhD
MD Anderson Cancer Center
11:50 – 12:10
Q&A 12:10 – 12:15
Metformin in Li Fraumeni Syndrome: High Risks with Potential for High Reward Sharon Savage, MD
Division of Cancer Epidemiology & Genetics, NCI
12:15 – 12:35
Q&A 12:35 – 12:40
Synthetic DNA Immunotherapy for High Risk Disease and Cancer: Clinical examples from HPV CIN, VIN & AIN /Cancer and Immune Studies Targeting Nonviral Cancers David Weiner, PhD
The Wistar Institute and Director of the Vaccine Center
12:40 – 1:10 LUNCH
SPECIAL SESSION
1:10 – 2:20
Moderator: Howard Parnes, MD
Division of Cancer Prevention, NCI
1:10 – 1:35
Q&A 1:35 – 1:45
Multiplicity: Primary, Secondary, and Exploratory Endpoints Victor Kipnis, PhD
Division of Cancer Prevention, NCI
1:45 – 2:10
Q&A 2:10 – 2:20
PREVENT: Agents on the Horizon Shizuko Sei, MD
Division of Cancer Prevention, NCI
Concluding Remarks
2:20 – 2:30

Howard Parnes, MD
Division of Cancer Prevention, NCI

Powel Brown, MD, PhD
MD Anderson Cancer Center